Table 7.
Change in serum aspartate aminotransferase levels in individual studies
| Study |
Serum AST levels (IU/L) |
P value | P value between groups | ||
| Group | Baseline | Study completion | |||
| Kuchay et al[11] | Empagliflozin | 44.6 (23.5) | 36.2 (9.0) | 0.04 | 0.212 |
| Control | 45.3 (24.3) | 44.6 (23.8) | 0.931 | ||
| Ito et al[12] | Ipragliflozin | 39.7 (16.7) | 27.3 (8.9) | < 0.05 | 0.802 |
| Pioglitazone | 43.3 (20.5) | 32.4 (15.4) | < 0.05 | ||
| Eriksson et al[14] | Placebo | 29.4 (13.2) | -1.2 (7.2)1 | - | - |
| Omega-3 CA | 30.6 (10.2) | +4.8 (9.0)1 | - | Non-significant2 | |
| Dapagliflozin | 31.2 (11.4) | -4.2 (5.4)1 | - | < 0.052 | |
| O + D | 30 (10.2) | +1.2 (5.4)1 | - | Non-significant2 | |
| Ohki et al[15] | Ipragliflozin | 37 (29.0-52.0) | 28 (23.0-31.0) | 0.03 | - |
| Seko et al[16] | SGLT-2 inhibitor | 54.4 (5.6) | 38 (3.1) | 0.001 | - |
| Sitagliptin | 67 (7.7) | 52.5 (7.7) | 0.016 | ||
| Gautam et al[17] | Canagliflozin | 72 (16.7) | 53 (10.3) | < 0.00001 | - |
| Sumida et al[18] | Luseogliflozin | 40.7 (22.2) | 31.9 (18.2) | < 0.001 | - |
1
Change from baseline.
2
Compared to placebo.
AST: Aspartate aminotransferase; CA: Carboxylic acid; O + D: Omega-3 carboxylic acid + Dapagliflozin; SGLT-2: Sodium glucose cotransporter-2.